According to Australian rheumatologist Ranjeny Thomas, MD, Professor of Rheumatology and Head of the Autoimmunity Programme at the University of Queensland Diamantina Institute, by using tolerance-inducing antigen-specific strategies and dendritic cells, the field of rheumatology is moving ever closer to developing more effective immunotherapies that may eventually achieve greater drug specificity with lower toxicity, and perhaps even the potential to develop agents that could control or even prevent rheumatoid arthritis (RA).
Researchers have analyzed the genetic makeup of hundreds of endometrial tumors that may lead to targeted therapies for subpopulations of patients with this deadly cancer. Endometrial cancer, which affects the lining of the uterus, is the fourth most common cancer among women in the United States. Although most of the patients with type I endometrial cancer are cured, patients with type II endometrial cancer have few treatment options.
In Search of £1 Million to Confirm Value of First Genetically Engineered Oncolytic Virus for Neuroendocrine Cancer
Neuroendocrine cancer, a rare type of cancer (that became well known after Steve Jobs was diagnosed with and died from a neuroendocrine cancer of the pancreas), may have a new lease on life, if Swedish researchers of Uppsala University in Sweden find a way of obtaining £1 million (approximately $1.5 million) to support their research.
Only 9 days after the US Food and Drug Administration (FDA) approved radium RA 223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) on May 15, 2013, which was 3 months ahead of the scheduled FDA review, the first worldwide commercial dose of this new therapy was administered to a patient with advanced CRPC. This event was made possible by a joint effort between 3 urology clinics in Myrtle Beach, SC, that constitute a division of 21st Century Oncology.
Disease Burden, Not Inefficiency in Care, Explains the Lion Share of Geographical Differences in Medicare Costs
A novel study offers a new explanation for the geographical differences seen in Medicare costs across the nation. Unlike the explanation offered mainly by the Dartmouth Atlas of Health Care and other research attributing geographical variations in care to waste and inefficiency in the delivery of healthcare, “our results suggest that the portion of the geographic variation that can be explained by patient health is much greater than previously estimated, leaving less of the geographic variation potentially attributable to inefficiency,” wrote James D.
After a decade of developing molecular diagnostics for lung cancer, 3 organizations have issued the first guidelines for testing for the EGFR mutation and ALK rearrangement in patients with lung cancer, the number one cancer-related killer worldwide, providing a valuable new tool to fully utilize the benefits of targeted therapies for this patient population.
Endometrial cancer is the fourth most common malignancy among American women. The National Cancer Institute estimates that close to 50,000 women will be diagnosed with endometrial cancer in 2013; for a majority of women with aggressive, high-grade tumors, the 5-year survival rate is approximately 16%.
Using data-sifting algorithms developed by computer scientists at Brown University, researchers are beginning to untangle the complex genetics of cancer. In a new study published in the New England Journal of Medicine, investigators have outlined the most complete genetic profile of acute myeloid leukemia (AML). This research is expected to lead to new treatments for AML based on the unique genetics of each patient.
Page 10 of 21
Results 91 - 100 of 205
Results 91 - 100 of 205